NR1D2 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the body. Acupuncture is a pseudoscience; the theories and practices of TCM are not based on scientific knowledge, and it has been characterized as quackery. There is a range of acupuncture technological variants that originated in different philosophies, and techniques vary depending on the country in which it is performed. However, it can be divided into two main foundational philosophical applications and approaches; the first being the modern standardized form called eight principles TCM and the second being an older system that is based on the ancient Daoist wuxing, better known as the five elements or phases in the West. Acupuncture is most often used to attempt pain relief, though acupuncturists say that it can also be used for a wide range of other conditions. Acupuncture is typically used in combination with other forms of treatment. The global acupuncture market was worth US$24.55 billion in 2017. The market was led by Europe with a 32.7% share, followed by Asia-Pacific with a 29.4% share and the Americas with a 25.3% share. It was estimated in 2021 that the industry would reach a market size of US$55 billion by 2023. The conclusions of trials and systematic reviews of acupuncture generally provide no good evidence of benefits, which suggests that it is not an effective method of healthcare. Acupuncture is generally safe when done by appropriately trained practitioners using clean needle techniques and single-use needles.
== Other uses == Pregnancy tests may be used to predict if a pregnancy is likely to continue or is abnormal. Miscarriage, or spontaneous abortion or pregnancy loss, is common in early pregnancy. Serial quantitative blood tests may be done, usually 48 hours apart, and interpreted based on the knowledge that hCG in a viable normal pregnancy rises rapidly in early pregnancy. For example, for a starting hCG level of 1,500 mIU/ml or less, the hCG of continuing, normal pregnancy will increase at least 49% in 48 hours. However, for pregnancies with a higher starting hCG, between 1,500 and 3,000 mIU/ml, the hCG should rise at least 40%; for a starting hCG greater than 3,000 mIU/ml, the hCG should increase at least 33%. Failure to rise by these minimums may indicate that the pregnancy is not normal, either as a failed intrauterine pregnancy or a possible ectopic pregnancy. Ultrasound is also a common tool for determining viability and location of a pregnancy. Serial ultrasound may be used to identify non-viable pregnancies, as pregnancies that do not grow in size or develop expected structural findings on repeated ultrasounds over a 1–2 week interval may be identified as abnormal. Occasionally, a single ultrasound may be used to identify a pregnancy as non-viable; for example, an embryo that is greater than a certain size but that lacks a visible heart beat may be confidently determined to be not viable without the need for follow up ultrasound for confirmation.
=== Figure skating scandals === Attack on Nancy Kerrigan - Nancy Kerrigan was attacked after a practice session at the 1994 U.S. Figure Skating Championships. Kerrigan's main team competitor, Tonya Harding, was accused of being involved in the attack. Kamila Valieva's failed drug test - Kamila Valieva failed a drug test for a banned heart medication in December 2021. This drug test result only surfaced after the figure skating team event in the 2022 Beijing Olympic Games, in which she competed for the ROC. Despite the result of the drug test, Kamila Valieva was cleared to skate in the Beijing 2022 singles event by the Court of Arbitration for Sport the following week, as she was considered a protected person due to being only 15 years of age. This decision was highly controversial and has resulted in the minimum age for competing in the Olympic Games for figure skating to rise from 15 years of age to 17 years of age.
Sources: en.wikipedia.org
Oxycodone/aspirin (trade name Percodan) is a combination drug marketed by Endo Pharmaceuticals. It is a tablet containing a mixture of 325 mg (5 grains) of aspirin and 4.8355 mg of oxycodone HCl (equivalent to 4.3346 mg of oxycodone as the free base); it is an opioid/non-opioid combination used to treat moderate to moderately severe pain. The safety of the combination during pregnancy has not been established, although aspirin is generally contraindicated during pregnancy, and the drug has been placed in pregnancy category D. Inactive ingredients include D&C Yellow 10, FD&C Yellow 6, microcrystalline cellulose, and corn starch. Percodan was first marketed by DuPont Pharmaceuticals and prescribed in the United States in 1950. Once a widely prescribed painkiller, it has largely been replaced by alternative oxycodone compounds containing paracetamol (acetaminophen) instead of aspirin, such as Percocet.
== Pharmacology == Since pembrolizumab is cleared from the circulation through non-specific catabolism, no metabolic drug interactions are expected and no studies were done on routes of elimination. The systemic clearance [rate] is about 0.2 L/day and the terminal half-life is about 25 days.
=== Freeze drying === Originally introduced in 1813 by William Hyde Wollaston to the Royal Society in London, it was not until the late 80's the freeze-drying industry discovered the allurement and longevity of freeze-dried flowers. Freeze-dried flowers are fresh flowers that have been specially dried to preserve their natural shape and color. Freeze drying is accomplished by a process called sublimation. It requires a special freeze-drying machine. It involves first freezing the flowers at 100K for at least 12 hours. A vacuum pump slowly pulls the moisture out of the flowers as a vapor in one chamber, and then the vapor condenses as ice in another chamber. Because of this process, the shape and natural color of the flower is maintained. It has been found that certain flowers retain their color well despite the fact they have been freeze-dried. Apparently, such flowers retain their color due to the tissue composition of the petals, leaves, and the like. Carnations, African violets, roses, asparagus and other ferns, and baby's breath exhibit good color retention notwithstanding the dehydration during the freeze-drying process. Those floral pieces which either dull or fade from dehydration may be given color by utilization of a florist's spray tint. This spray coloring restores the lost color which, in the sealed environment of the glass container of the final product, retains its given color along with the natural color of the other pieces.
Sources: en.wikipedia.org
==== Acetylcholine synthesis ==== Acetyl-CoA is also an important component in the biogenic synthesis of the neurotransmitter acetylcholine. Choline, in combination with acetyl-CoA, is catalyzed by the enzyme choline acetyltransferase to produce acetylcholine and coenzyme A as a byproduct.
== Adverse effects == The use of clinafloxacin is associated with drug-induced light sensitivity (phototoxicity) and low blood sugar. Diarrhea has also been reported. The phototoxicity with clinafloxacin has been more associated with oral dosing as compared to intravenous dosing, though the studies that described this were subject to confounding by study site (that is, patients that received intravenous clinafloxacin were less mobile, and thereby received less sunlight exposure). The mechanism for clinafloxacin's phototoxicity involves the chlorine atom at position 8. In the presence of ultraviolet light, the chemical structure of clinafloxacin is degraded, resulting in the formation of toxic, reactive oxygen species that can damage cellular structures—including DNA. For this reason clinafloxacin can also be classified as a photocarcinogen (a chemical that can cause light-induced cancer), though the risk of developing cancer in humans taking the medication is small. The mechanism for clinafloxacin's effect on blood glucose is thought to involve stimulation of the pancreatic beta cells, which produce insulin (a hormone that lowers blood glucose levels). The symptoms of clinafloxacin overdose are unknown.
ACC synthase reaches optimal activity in conditions of pH 8.5 and with Km = 20 um relative to its substrate, SAM. ACC Synthase and ethylene biosynthesis are regulated by a whole host of stimuli. Stresses such as wounding, noxious chemicals, auxin, flooding, and indole-3-acetic acid (IAA) promote ethylene synthesis, creating a positive feedback cycle with ACC synthase, up-regulating its activity. However, it is also inhibited by a number of compounds as well. S-Adenosylethionine can bind as a substrate for ACC synthase (with higher affinity than SAM) and therefore inhibit any reaction with SAM. ACC Synthase is also competitively inhibited by aminoethoxyvinylglycine (AVG) and aminooxyacetic acid (AOA), inhibitors to many pyridoxal phosphate-mediated enzymic reactions. They are natural toxins that cause slow binding inhibition by interfering with the coenzyme pyridoxal phosphate. ACC synthase activity is also inhibited by intermediates of the activated methyl cycle and the methionine-recycling pathway: 5′-methylthioadenosine, α-keto-γ-methylthiobutyric acid, and S-adenosylhomocysteine.
=== Strontium === The addition of lime to soils which are poor in calcium can reduce the uptake of strontium by plants. Likewise in areas where the soil is low in potassium, the addition of a potassium fertilizer can discourage the uptake of cesium into plants. However such treatments with either lime or potash should not be undertaken lightly as they can alter the soil chemistry greatly, so resulting in a change in the plant ecology of the land.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.